Tofaxen (Tofacitinib) Tablets

Indicated for the treatment of adult patients with:

• 🔹 Rheumatoid Arthritis (RA): Moderate to severe active RA.
• 🔹 Psoriatic Arthritis: Active psoriatic arthritis (usually used in combination with non-biologic DMARDs).
• 🔹 Ulcerative Colitis: Moderately to severely active disease (induction and maintenance).
• 🔹 Ankylosing Spondylitis: Active disease requiring systemic therapy.

Packaging: 5 mg film-coated tablets.

⚠️ ADMINISTRATION PROTOCOL:

• Standard Dose: 5 mg taken twice daily.
• For Ulcerative Colitis: Initial dose may be 10 mg twice daily for at least 8 weeks, followed by a maintenance dose of 5 mg twice daily, as prescribed by a physician.
• Administration: Swallow whole with water. Can be taken with or without food.
• Adjustment: Dosage may need adjustment in patients with moderate renal or hepatic impairment.

• Active serious infections (e.g., tuberculosis, sepsis).
• Severe hepatic impairment.
• Pregnancy and breastfeeding (potential risk to the fetus).
• Known hypersensitivity to Tofacitinib.

Common and serious adverse reactions include:

• 🦠 Infections: Upper respiratory tract infections, nasopharyngitis, herpes zoster (shingles).
• 🩸 Labs: Increased cholesterol levels (dyslipidemia), headache.
• 🌀 Physical: Diarrhea, hypertension, nausea.
• ⚠️ Warning: Increases the risk of serious infections and thrombosis. Regular blood monitoring is required.